7 Minutes
Viagra was designed for the heart, became famous for erections, and is now being talked about in a very different context: Alzheimer’s disease. That twist says a lot about where neuroscience is headed. With dementia cases rising globally and new drug development moving at a cautious pace, researchers are increasingly asking a pragmatic question—what if the next meaningful Alzheimer’s treatment is already sitting on a pharmacy shelf?
This approach has a name: drug repurposing. Instead of inventing an entirely new compound (a process that can take a decade or more), scientists evaluate medicines and vaccines with established safety records to see whether they can influence the biological pathways involved in neurodegeneration. Faster. Cheaper. Often safer for older adults, who are typically underrepresented in early-stage trials.
A recent expert-led review pushed that idea into the spotlight by ranking existing candidates that might help prevent or treat Alzheimer’s. Out of dozens of nominations, three stood above the rest: sildenafil (best known by the brand name Viagra), the shingles vaccine Zostavax, and riluzole, a drug prescribed for amyotrophic lateral sclerosis (ALS). None of them is an Alzheimer’s therapy today—but the panel’s endorsement gives these options extra weight as priorities for large, carefully monitored clinical trials.
A shortlist built by consensus, not hype
The review was assembled by 21 specialists who evaluated anonymous nominations alongside clinical data, epidemiological signals, and input that reflects real-world experience. To avoid groupthink and to make sure quieter evidence wasn’t drowned out by louder opinions, the team used a Delphi consensus process—an iterative method often used in medicine and public health when a group needs to converge on the strongest choices.
The result was a ranked list of 80 repurposing candidates with plausible links to dementia biology. But three rose to the top because they check several boxes at once: mechanistic rationale (a believable way they could work in the brain), supportive non-clinical research, and human evidence from population studies and/or early clinical investigations. Just as important, the panel emphasized tolerability—any candidate aimed at older adults must be suitable for frailer patients and compatible with the reality of long-term use.
The authors argued that each priority candidate has evidence supporting relevant mechanisms and enough preliminary support to justify the next expensive step: robust clinical trials designed specifically for Alzheimer’s prevention or treatment.
Why sildenafil keeps showing up in Alzheimer’s discussions
Sildenafil is a phosphodiesterase-5 (PDE5) inhibitor. In plain terms, it helps blood vessels relax and widen, improving blood flow. That’s why it works for erectile dysfunction—and why cardiology researchers originally paid attention to it.
So what does blood flow have to do with Alzheimer’s? Potentially, a lot. The aging brain is sensitive to vascular health, and impaired circulation has been linked to cognitive decline. Beyond that, earlier studies have connected sildenafil to shifts in molecular processes implicated in dementia, including the buildup of tau protein—one of the hallmark pathologies in Alzheimer’s disease. Tau tangles disrupt how neurons function and communicate; reducing toxic accumulation, if confirmed in controlled trials, would be a meaningful target.
Still, association is not causation. Observational findings can be influenced by who gets prescribed a medication in the first place, what other conditions they have, and how well they access healthcare. That’s why the panel’s message was essentially: promising enough to test properly, not strong enough to declare victory.
A vaccine signal: Zostavax and the immune system angle
In a surprising turn, the expert panel rated Zostavax—an older shingles vaccine—as even more compelling than sildenafil. The underlying relationship isn’t fully settled, but the direction of travel is intriguing. Several studies have reported that shingles vaccination correlates with a reduced risk of developing Alzheimer’s or other forms of dementia.
One hypothesis centers on immunology. Alzheimer’s is increasingly viewed not only as a disease of protein aggregates (amyloid and tau) but also as a disorder involving chronic inflammation and immune dysregulation in the brain. Vaccination may alter immune responses, reduce the burden of viral reactivation, or shift inflammatory signaling in ways that indirectly protect neural tissue. Researchers are still disentangling the mechanism, but the epidemiological signal has been difficult to ignore.
It’s also a reminder that dementia prevention might not come from a single “silver bullet” drug. It may emerge from interventions that reduce cumulative stress on the brain—vascular, metabolic, inflammatory, and infectious factors working in combination over decades.
Riluzole: protecting neurons by changing brain chemistry
Riluzole is used in ALS, a neurodegenerative disease that, like Alzheimer’s, involves progressive neuronal loss. Its pharmacology is complex, but it is often described as modulating glutamate signaling. Glutamate is a crucial neurotransmitter for learning and memory; in excess, it can contribute to excitotoxicity—essentially overstimulating neurons until they are damaged or die.
By influencing these pathways, riluzole has been investigated for neuroprotective potential in multiple contexts. For Alzheimer’s, the logic is straightforward: if a therapy can reduce stress on vulnerable neurons or slow pathways that lead to cell death, it could help preserve cognitive function—especially if administered early, before extensive damage accumulates.
Here again, the panel’s emphasis was not that riluzole is already an Alzheimer’s drug, but that it has enough mechanistic and early evidence to justify well-designed trials focused on meaningful endpoints such as cognitive decline, biomarkers, and daily functioning.
What happens next—and why it matters
Anne Corbett, a dementia researcher at the University of Exeter in the UK, has argued that progress against dementia will require “every avenue of research,” including smarter use of medicines we already understand. That’s the practical advantage of repurposing: known manufacturing pipelines, known side-effect profiles, and a clearer path to real-world deployment if efficacy is demonstrated.
The caution is equally important. Alzheimer’s disease is biologically tangled. Multiple contributors—protein aggregation, vascular changes, immune activity, and genetic risk—interact over time. A drug that looks promising in population data may fail in trials if the timing is wrong, the patient group is too broad, or the biological target is only relevant to a subset of cases.
That’s why the next phase must be rigorous clinical testing: randomized, controlled studies that can separate genuine protective effects from coincidence. If sildenafil, Zostavax-related immune effects, or riluzole’s neurochemical modulation hold up under that level of scrutiny, the payoff could be enormous: faster access to Alzheimer’s prevention tools, and a shift toward earlier, more personalized strategies in dementia care.
Source: sciencealert
Comments
datapulse
Solid idea, but repurposing isnt a shortcut. Timing, dose, patient mix will decide if any of these actually help. fingers crossed
Reza
Is this even true? Observational links can be deceptive - who gets prescribed matters, confounders everywhere.
labcore
Wow, Viagra for Alzheimer’s? wild twist, kinda hopeful but also uneasy. We need hard trials, not headlines!!
Leave a Comment